Source: Cure, August 2016
Patients with BRAF-positive advanced melanoma saw a 30 percent reduced risk of death with the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib), compared to treatment with Zelboraf alone, according to the final survival analysis of the phase 3 coBRIM study published in The Lancet Oncology.
The targeted combination improved median overall survival (OS) by 4.9 months versus single-agent Zelboraf. The OS rates for the combination at one and two years were 74.5 percent and 48.3 percent, respectively.
“Melanoma is one of the few cancers that has increased in incidence over the past 30 years, and until recently, people with advanced forms of the disease have had few treatment options. Five years ago, the survival of people with advanced melanoma was measured in months, and now we have medicines that are helping people live years,” Josina Reddy, senior group medical director at Genentech, the company that manufactures the combination, said in an interview with CURE.read the original full article